Photo of Paolo Tarantino taken from Twitter
Feb 11, 2024, 15:45
Paolo Tarantino: In a large RW cohort we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“In a large (≃1000) RW cohort from Dana Farber, consistently with prior reports, we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment. This only impacted prognosis if HER2+HER2-neg. Our latest article now out on EJC.”
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 21, 2025, 05:44
Jan 21, 2025, 05:12
Jan 21, 2025, 04:58
Jan 21, 2025, 04:17
Jan 20, 2025, 20:33
Jan 20, 2025, 20:31